Sight Sciences Inc (SGHT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $601.92M
Last updated: Nov 17, 2026 at 11:05 AM ET
Sight Sciences Inc (SGHT) Stock Forecast
Analysts expect Sight Sciences (SGHT) to earn -$0.46 per share in the fiscal year ending Dec 31, 2026, on revenue of $92.59M. Of 8 analysts, 6 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 12.5% |
| Buy | 5 | 62.5% |
| Hold | 2 | 25.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 12.2%.
- Fiscal year ending Dec 31, 2026
- -$0.46
- EPS consensus, revenue $92.59M
- Fiscal year ending Dec 31, 2027
- -$0.36
- EPS consensus, revenue $103.88M
- Next report
- Mar 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.46 | -$0.61 to -$0.28 | 6 | $92.59M | $92.00M to $92.95M | 8 |
| Dec 31, 2027 | -$0.36 | -$0.52 to -$0.20 | 6 | $103.88M | $101.30M to $105.41M | 8 |
Quarterly Estimates
The EPS consensus rises from -$0.14 for the quarter ending Dec 31, 2026 to -$0.12 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.17 to -$0.08 | 9 | $25.15M | $23.27M to $27.20M | 10 |
| Mar 31, 2027 | -$0.12 | -$0.16 to -$0.07 | 4 | $22.88M | $22.50M to $23.13M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.49.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.46 | -$0.49 | -$0.49 | -$0.49 | -$0.49 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.36 | -$0.40 | -$0.43 | -$0.43 | -$0.43 | N/A |
| Quarter ending Mar 31, 2027 | -$0.12 | -$0.07 | -$0.06 | -$0.06 | -$0.06 | N/A |
Frequently Asked Questions About SGHT
What is the SGHT stock forecast?
Consensus analyst estimates put Sight Sciences's EPS at -$0.46 for the fiscal year ending Dec 31, 2026, on revenue of $92.59M. The consensus rating from 8 analysts is Buy.
How do analysts rate SGHT stock?
Of 8 analysts covering Sight Sciences, 1 rates it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SGHT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.46, with estimates from -$0.61 to -$0.28 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.36, with estimates from -$0.52 to -$0.20 from 6 analysts.
What revenue do analysts expect from Sight Sciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $92.59M, with estimates from $92.00M to $92.95M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $103.88M, with estimates from $101.30M to $105.41M.
How many analysts cover SGHT?
8 analysts rate Sight Sciences stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SGHT pages: Overview, Earnings, Forecast, Financials, Competitors